17,261 trials
Complex Atypical Hyperplasia · Endometrial Cancer
Primary: Complete Response Rate - 6 Months — 80 percentage of participants
Antibiotic Resistant Infection · Nosocomial Infection · Pathogen Transmission
Primary: Within-individual Change in SCFA Producer Level — -0.0; -1.8; 1.1 percentage of SCFA producers
Lung Cancer
Primary: Change From Baseline in Bronchial Dysplasia Index at 12 Months — 1.67; 1.62; 1.55; 1.48 score — p=0.452
Cholangiocarcinoma
Primary: Objective Response Rate (ORR) — 2 Participants
Multiple Sclerosis
Primary: Assess the Effect of NBT-NM108 on Serum TNF-alpha Levels in MS Patients — 25.62; 22.58; 20.73 pg/ml
High-grade Serous Ovarian Carcinoma · Ovarian Carcinoma
Primary: Change From Baseline in Circulating Tumor Deoxyribonucleic Acid (ctDNA) — 0.08; 0.04 Fold change
Chronic Sinusitis · Chronic Rhinosinusitis (Diagnosis)
Primary: Product-related Unexpected Serious Adverse Events — 0; 0; 0 Participants
Indolent Systemic Mastocytosis
Primary: Percent Change in Quality of Life (QoL) Using Mastocytosis Quality of Life Questionnaire (MC-QoL) — 38.98; 33.02 percentage of change in quality of life — p=0.7740
Covid19
Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) Within the CX-4945 Treatment Group — 9; 4 Participants
Ovarian Cancer
Primary: Occurrence of Palmar-plantar Erythrodysesthesia (PPE) — 18; 9; 3; 0 Participants
Head and Neck Squamous Cell Carcinoma · Malignant Solid Neoplasm
Primary: Phase I: The Recommended Phase II Dose Determenation. Phase II: Overall Response Rate (ORR) and Progression Free Survival (PFS) — 40 mg
Hypertension
Primary: Number of Participants With Any Treatment-emergent Adverse Events (TEAEs) — 73 Participants
IDH1 Mutation · IDH2 Mutation · Recurrent Glioblastoma
Primary: Participants With Dose Limiting Toxicity (DLT) Rate Less Than or Equal to 33% (Dose Level 1) — 0; 7 Participants
Erosive Osteoarthritis
Primary: CTX-I (C-terminal Telopeptide of Type I Collagen ) Bone Turnover Marker Levels — 0.05; 0.06; 0.63; 0.33 ng/ml — p=<0.01
Breast Cancer · Estrogen Receptor Positive Tumor · HER2-positive Breast Cancer
Primary: Pathological Complete Response (pCR) — 24; 24 Participants